Merck announces collaboration with Iktos for generative artificial intelligence (AI) technology
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced a collaboration agreement with Iktos, for the use of its generative modelling artificial intelligence (AI) technology, in order to facilitate the rapid and cost-effective discovery and design of promising new compounds.
Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW
- Details
- Category: Novartis
Sandoz, a Novartis division, announced the winners of the 2019 Sandoz Healthcare Access Challenge (HACk). Sandoz HACk invites entrepreneurs and innovators in the field of digital technology to submit ideas with the potential to complement - or even positively disrupt - established approaches to driving access to healthcare.
Impact pioneers honored for groundbreaking ideas in the fields of healthcare and nutrition
- Details
- Category: Bayer
The Bayer Cares Foundation recently presented the 2018 Aspirin Social Innovation Awards to five international initiatives for their groundbreaking ideas in the fields of healthcare and nutrition. The award-winners are all impact pioneers whose concepts have the potential to bring about sustainable, systematic changes to thus improve the living conditions of hundreds of millions of people worldwide.
Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors
- Details
- Category: Novo Nordisk
Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this 30 week trial was to assess the efficacy and safety of Ozempic® (semaglutide) 1.0 mg when added to SGLT-2 inhibitor (SGLT-2i) therapy.
Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
- Details
- Category: Novartis
Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab). The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9% achieved PASI 90 by week 12, with 87% of patients reaching PASI 90 by week 16.
Bayer Thrombosis Research Award 2019 goes to Dr. Changjun Yin
- Details
- Category: Bayer
The fourth winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation awarded the EUR 30,000 prize to Dr. Changjun Yin from the Institute for Cardiovascular Prevention at the Ludwig-Maximilians-University in Munich in recognition of his research on Atherosclerosis and Alzheimer's disease (AD) as inflammatory conditions with high risks to develop thrombosis-related diseases.
Jury upholds Amgen's patents on Repatha® (evolocumab)
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These patents describe and claim antibodies, like Amgen's innovative Repatha® (evolocumab) product, that bind to a specific region on PCSK9 and reduce LDL-C levels in the body.
More Pharma News ...
- Roche enters into definitive merger agreement to acquire Spark Therapeutics
- Brilinta’s Phase III THEMIS trial met primary endpoint in patients with established coronary artery disease and type-2 diabetes
- Amgen, Cytokinetics and Servier announce start of METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure
- Abbott and Novo Nordisk enter partnership to provide integrated digital solution to people with diabetes using insulin
- Ochsner Health System and Pfizer partner to develop innovative models for clinical trials
- Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
- Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)